8/31 6:00 - 8:00, Arrillaga Alumni Center, Fisher Room
Chief Scientific Officer, MLC Dx
Dr. Faham developed a SNP discovery technology during his postdoctoral research in Ron Davis lab at Stanford Genome Technology Center. He went on to co-found ParAllele Biosciences in 2001 as Director of Research. ParAllele's technologies were adopted by many customers and used for polymorphism detection and genotyping by multiple pharmaceutical and academic partners, including the HapMap project. The company was acquired by Affymetrix for $120M in 2005, and Dr. Faham transitioned into VP Research, Oncology Technology where he remained until 2008. During that time he spearheaded the development of multiple genomic technologies that combined different methods for specific highly multiplexed amplifications with array readouts. These were applied to analysis of copy number from formalin fixed samples, high resolution promoter methylation, and high throughput high accuracy array resequencing. He recently co-founded and obtained funding for a new company (MLC Dx) in the molecular diagnostics space where he is currently CSO. Dr. Faham obtained a Ph.D. in human genetics and an MD (board eligible in Psychiatry) from the University of California San Francisco. He has published more than 25 articles and is an inventor on more than 15 patents.